Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 25 2017 - 04:05PM
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it
will report its second quarter 2017 financial results and provide a
corporate update on August 1, 2017. The Company will also host a
conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the
United States or 1-847-585-4405 internationally approximately 10
minutes before the start of the call. The passcode is
45276605.
A replay will be available through August 15,
2017 at 1-888-843-7419 from the United States and 1-630-652-3042
internationally. The passcode will be 45276605.
About Corcept Therapeutics
Incorporated
Corcept is a pharmaceutical company engaged in
the discovery, development and commercialization of drugs that
treat severe metabolic, oncologic and psychiatric disorders by
modulating the effects of cortisol. Korlym®, a
first-generation cortisol modulator, is the company’s first
FDA-approved medication. The company has a portfolio of proprietary
compounds that modulate the effects of cortisol but not
progesterone. Corcept owns extensive intellectual property covering
the use of cortisol modulators, including mifepristone, in the
treatment of a wide variety of serious disorders. It also holds
composition of matter patents covering its selective cortisol
modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2023 to Mar 2024